Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sergio Chimenti

Showing results (131-140 of 217) with videos related to

Pageof 22
Sort By:
Clinicoeconomics and Outcomes Research : CEOR|September 22, 2011
A cost-utility analysis of etanercept for the treatment of moderate-to-severe psoriasis in ItalyGiorgio L Colombo, Sergio Di Matteo, Ketty Peris, et al.
Journal of the American Academy of Dermatology|June 19, 2007
Adalimumab for severe psoriasis and psoriatic arthritis: an open-label study in 30 patients previously treated with other biologicsMarina Papoutsaki, Maria-Sole Chimenti, Antonio Costanzo, et al.
Archives of Dermatology|January 21, 2009
Relation between animal-type melanoma and reduced nuclear expression of glutathione S-transferase piAugusto Orlandi, Sara Costantini, Elena Campione, et al.
Lancet (London, England)|August 16, 2014
Oral ponesimod in patients with chronic plaque psoriasis: a randomised, double-blind, placebo-controlled phase 2 trialAndrea Vaclavkova, Sergio Chimenti, Petr Arenberger, et al.
The Journal of Dermatological Treatment|August 2, 2011
Efficacy and tolerability of 5-aminolevulinic acid 0.5% liposomal spray and intense pulsed light in wrinkle reduction of photodamaged skinAntonella Piccioni, Maria Concetta Fargnoli, Spyridon Schoinas, et al.
Cell Cycle (Georgetown, Tex.)|August 26, 2006
Cross-talks in the p53 family: deltaNp63 is an anti-apoptotic target for deltaNp73alpha and p53 gain-of-function mutantsMauro Lanza, Barbara Marinari, Marina Papoutsaki, et al.
Drug Development Research|November 11, 2014
Treatment adherence to different etanercept regimens, continuous vs. intermittent, in patients affected by plaque-type psoriasisMaria Esposito, Paolo Gisondi, Nicoletta Cassano, et al.
Current Medical Research and Opinion|April 6, 2016
Long-term use of a new topical formulation containing piroxicam 0.8% and sunscreen: efficacy and tolerability on actinic keratosis. A proof of concept studyGraziella Babino, Laura Diluvio, Luca Bianchi, et al.
Dermatology (Basel, Switzerland)|August 19, 2004
Psoriasis, Kaposi's sarcoma and Hodgkin's disease in a patient with Down's syndromeMaria Concetta Fargnoli, Ketty Peris, Pasquale Frascione, et al.
Oncogene|July 12, 2005
A p38-dependent pathway regulates DeltaNp63 DNA binding to p53-dependent promoters in UV-induced apoptosis of keratinocytesMarina Papoutsaki, Francesca Moretti, Mauro Lanza, et al.
Pageof 22

Showing results (131-140 of 217) with videos related to

Sort By:
Pageof 22
Clinicoeconomics and Outcomes Research : CEOR|September 22, 2011
A cost-utility analysis of etanercept for the treatment of moderate-to-severe psoriasis in ItalyGiorgio L Colombo, Sergio Di Matteo, Ketty Peris, et al.
Journal of the American Academy of Dermatology|June 19, 2007
Adalimumab for severe psoriasis and psoriatic arthritis: an open-label study in 30 patients previously treated with other biologicsMarina Papoutsaki, Maria-Sole Chimenti, Antonio Costanzo, et al.
Archives of Dermatology|January 21, 2009
Relation between animal-type melanoma and reduced nuclear expression of glutathione S-transferase piAugusto Orlandi, Sara Costantini, Elena Campione, et al.
Lancet (London, England)|August 16, 2014
Oral ponesimod in patients with chronic plaque psoriasis: a randomised, double-blind, placebo-controlled phase 2 trialAndrea Vaclavkova, Sergio Chimenti, Petr Arenberger, et al.
The Journal of Dermatological Treatment|August 2, 2011
Efficacy and tolerability of 5-aminolevulinic acid 0.5% liposomal spray and intense pulsed light in wrinkle reduction of photodamaged skinAntonella Piccioni, Maria Concetta Fargnoli, Spyridon Schoinas, et al.
Cell Cycle (Georgetown, Tex.)|August 26, 2006
Cross-talks in the p53 family: deltaNp63 is an anti-apoptotic target for deltaNp73alpha and p53 gain-of-function mutantsMauro Lanza, Barbara Marinari, Marina Papoutsaki, et al.
Drug Development Research|November 11, 2014
Treatment adherence to different etanercept regimens, continuous vs. intermittent, in patients affected by plaque-type psoriasisMaria Esposito, Paolo Gisondi, Nicoletta Cassano, et al.
Current Medical Research and Opinion|April 6, 2016
Long-term use of a new topical formulation containing piroxicam 0.8% and sunscreen: efficacy and tolerability on actinic keratosis. A proof of concept studyGraziella Babino, Laura Diluvio, Luca Bianchi, et al.
Dermatology (Basel, Switzerland)|August 19, 2004
Psoriasis, Kaposi's sarcoma and Hodgkin's disease in a patient with Down's syndromeMaria Concetta Fargnoli, Ketty Peris, Pasquale Frascione, et al.
Oncogene|July 12, 2005
A p38-dependent pathway regulates DeltaNp63 DNA binding to p53-dependent promoters in UV-induced apoptosis of keratinocytesMarina Papoutsaki, Francesca Moretti, Mauro Lanza, et al.
Pageof 22